About Juvenescence
Juvenescence is a company based in Dublin (Ireland) founded in 2017 by Greg Bailey. Juvenescence has raised $289.89 million across 7 funding rounds from investors including M42, Fastforward Innovations and IDO Investments. Juvenescence has completed 1 acquisition, including Ro5. Juvenescence offers products and services including Aging Medicines and AI-Enabled R&D Tools. Juvenescence operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Dublin, Ireland
- Founders Greg Bailey
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Juvenescence
Juvenescence offers a comprehensive portfolio of products and services, including Aging Medicines and AI-Enabled R&D Tools.
Medicines targeting core aging processes for disease prevention.
Tools integrating AI to design and accelerate drug development.
People of Juvenescence
Unlock access to complete
Unlock access to complete
Funding Insights of Juvenescence
Juvenescence has successfully raised a total of $289.89M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $76 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Juvenescence
Juvenescence has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include M42, Fastforward Innovations and IDO Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startups are targeted for investments by this venture capital firm.
|
Locked | Locked | Locked | |
|
Early-late stage tech-focused venture capital firm
|
Locked | Locked | Locked | |
|
Tech & life Science focused early stage VC firm investing in North America & Europe
|
Locked | Locked | Locked |
Investor details for Juvenescence
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Juvenescence
Juvenescence has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ro5.
Investment portfolio details for Juvenescence
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based drug discovery management tool is provided for researchers.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Juvenescence
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Juvenescence
Detailed financials for Juvenescence
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Juvenescence Comparisons
Peer comparison for Juvenescence
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Juvenescence
Juvenescence operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Juvenescence
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Juvenescence
Complete news archive for Juvenescence
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Juvenescence
Juvenescence was founded in 2017.
Juvenescence is headquartered in Dublin, Ireland.
Greg Bailey is the current CEO of Juvenescence. They have also founded this company.
Juvenescence is a funded company, having raised a total of $289.89M across 7 funding rounds to date.
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. The company offers keto-diet-based exogenous ketone which helps in metabolic switches and provides anti-aging properties and protection from other age-related diseases like neurodegenerative diseases, immunosenescence cell damage. The product is C6 Ketone Di-Ester which can raise the levels of ketones in the blood to generate ketosis.
Juvenescence's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Juvenescence offers Aging Medicines and AI-Enabled R&D Tools.
Juvenescence has made 1 acquisition, including Ro5.
Juvenescence has 8 investors. Key investors include M42, Fastforward Innovations, IDO Investments, Grok Ventures, and Ipgl.